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Background: The identification of serial miRNAs targeting the same functional gastric protein could provide new
and effective serological biomarkers for the diagnosis of gastric cancer (GC). The aim of this study was to evaluate
the potential of miR-20a-5p, let-7a and miR-320a in the diagnosis of AG or GC and the correlation of the three
miRNAs with their predicted target molecules PGA, PGC and PGA/PGC ratio.
Methods: The total of 291 patients included 103 controls (CON), 94 with atrophic gastritis (AG) and 94 with GC.
The levels of serum miRNAs were detected by quantitative reverse transcription-polymerase chain reaction and
serum pepsinogen A (PGA) and C (PGC) were determined by enzyme-linked immunosorbent assays.
Results: Serum miR-320a level decreased through the controls, AG and GC groups which were the cascades of GC
development, while there were no significant differences in levels of miR-20a-5p and let-7a among the controls, AG
and GC groups. When stratified by gender and age, serum miR-320a expression was lower in female GC patients
than in controls (p = 0.035), especially in female GC patients older than 60 years (p = 0.008). For distinguishing
female GC patients aged over 60, the area under the receiver operating characteristic curve for miR-320a was 0.699,
and the best cut-off point was 4.76 with a sensitivity of 65.2% and specificity of 68.2%. Concerning the correlations
between the selected miR-20a-5p, let-7a, miR-320a and PGs, we found that there were positive correlations
between all the three and the ratio of PGA/PGC (r = 0.408, 0.255, 0.324; p = <0.001, 0.009, 0.001, respectively), but
there was no relationship between the expression of serum miR-20a-5p and its predicted target PGA, or between
let-7a and miR-320a and their predicted target PGC. Serum miR-320a was decreased and PGC was increased in the
GC group compared with the control group.
Conclusions: Levels of serum miR-320a were lower in female GC patients older than 60 than in controls, which
may provide a potential valuable marker for diagnosing older women with GC. The levels of serum miR-20a-5p,
let-7a and miR-320a were positively correlated with PGA/PGC, which may indirectly reflect the functional status of
the gastric mucosa.
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It is essential to explore sensitive, specific and non-invasive
tumour biomarkers that can be used for early diagnosis, es-
timating prognosis, and forecasting recurrence. MicroRNAs
(miRNAs) are a class of highly conserved and endogenous
non-coding RNAs 19–24 nucleotides long, which regulate
the expression of target genes at the post-transcriptional
level. Accumulating evidence indicates that miRNAs are in-
volved in important biological processes related to prolifer-
ation, apoptosis, differentiation, metastasis, angiogenesis
and immune response, while deregulation of miRNAs may
be crucial in cancer initiation, progression and treatment
outcome [1,2]. It has recently been shown that human
serum or plasma contains large amounts of stable miRNAs,
the expression profiles of which could potentially be used
to identify various types of cancer, including prostate can-
cer, large B-cell lymphoma, ovarian cancer, liver cancer and
non-small cell lung cancer [3-7].
miRNAs are part of a complex regulatory network;
multiple genes can be regulated by one miRNA, but a
single gene may also be subtly regulated by a group of
miRNAs [2]. Few studies have investigated the associ-
ation between serum miRNAs and gastric diseases [8,9],
several studies focused on the plasma miRNAs expres-
sion [10-12], Liu H et al. identified miR-378 as a serum
biomarker [8], and Liu R et al. selected five miRNAs
(miR-1,-20a,-27a,-34 and −423-5p) as a fingerprint for
GC diagnosis [9]. But no attention has been paid to
targeting of the same gene by serial miRNAs. However,
such studies could help to clarify the common functions
of serial miRNAs targeting individual genes and thus im-
prove our understanding of their roles in gastric cancer
(GC) and precancerous diseases.
Human pepsinogens (PGs) are inactive pro-enzymes of
the specific digestive enzyme pepsin, which originate from
the gastric mucosa and can be classified biochemically and
immunochemically into PGA and PGC [13,14]. Previous
studies showed that PGC expression was negatively corre-
lated with the degree of malignancy of the gastric mucosa
and the development of gastric lesions [15]. A low PGA/
PGC ratio can be used as a serological biomarker of atro-
phic gastritis (AG), which is known to be a precancerous
condition [15,16]. Several miRNAs have been identified by
two target gene-predicting software packages (MicroCosm
Targets and TargetScan Human), some of which targeted
PGA (miR-212, miR-132, miR-20a-5p, miR-93) or PGC
(miR-662, miR-365, let-7a, miR-320a). The miRNAs
closely related to GC or other malignancies were selected
for further investigation in the current study. miR-20a-5p,
a member of the miR-17-92 cluster, was upregulated in
gastric, colorectal and pancreatic adenocarcinomas in situ
[17-19], tissue expression of let-7a was correlated with
lymph node metastasis of GC[20], and miR-320a was
down-regulated in primary breast cancer and correlatedwith invasion and metastasis [21-23]. These three miRNAs
have only previously been investigated in situ, and most
studies have focused on their functions; no studies have
investigated their potential roles as serum biomarkers for
the diagnosis of GC and precancerous disease. And
whether the predicted functional miRNAs (miR-20a-5p,
let-7a and miR-320a) could be identified as a biomarker
for the diagnosis of GC and precancerous disease? Fur-
thermore, their relationships with their predicted target
pepsinogen are unknown.
This study therefore aimed to evaluate the potential of
miR-20a-5p, let-7a and miR-320a in the diagnosis of GC
and the correlation of the three miRNAs and PGA, PGC
and PGA/PGC ratio. We investigated the serum levels of
the three selected miRNAs in GC and its precancerous
condition, as well as the correlation between serum
miR-20a-5p and its predicted target PGA, and between
serum let-7a and miR-320a and their predicted target
PGC. The results maybe identify several valuable sero-
logical markers for gastric diseases to some extent, as
well as providing experimental evidence and reference to
aid our further understanding of the functions of serum
miRNAs in the process of carcinogenesis.
Methods
Subjects
A total of 291 subjects who underwent gastroscopy ex-
aminations in the first Affiliated Hospital of China
Medical University from 2004 to 2011 were enrolled in
this study. Information about gender, age and other
factors was obtained by means of a questionnaire ad-
ministered to each subject. The study was approved by
the Human Ethics Review Committee of China Medical
University. Written informed consent was obtained
from participants in accordance with the Declaration of
Helsinki and its later revision. All patients underwent
endoscopic gastric mucosal biopsy, and the biopsy
specimens were paraffin-embedded and stained by HE
staining for histological diagnosis which was diagnosed
by two experienced pathologists. Cases with minimal
superficial gastritis were treated as the controls [24].
The atrophic gastritis group was defined according
to histopathology. The histopathology diagnoses was
included slight, moderate and severity, and only the
grade of moderate and severity was enrolled in this
case–control study. Ninety-four patients were histologi-
cally confirmed gastric adenocarcinoma cases; 75 could
be classified according to Lauren classification, while
19 could not. And among the 75 cases [25], 22 of the
75 GC cases were the intestinal type, 45 were the dif-
fuse type and 8 were the mixed type. The samples in
gastric cancer group matched in the age and gender
composition with patients with controls and with atro-
phic gastritis.
Table 1 Characteristics of the study subjects
Variables Control Atrophic gastritis Gastric cancer
n = 103 n = 94 n = 94
Gender
Male 65(63.1%) 61(64.9%) 59(62.8%)
Female 38(36.9%) 33(35.1%) 35(37.2%)
P = 0.948
Age(years)
Mean 59.1 ± 10.6 60.4 ± 11.2 60.2 ± 11.1
Range 23-80 28-83 27-80
P = 0.654
H.pylori infection status
Hp- 60(58.3%) 48(51.1%) 53(56.4%)
Hp+ 43(41.7%) 46(48.9%) 41(43.6%)
P = 0.580
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transcription-polymerase chain reaction (qRT-PCR) assay
Approximately 6 ml venous blood was collected from
each subject. Serum total RNA was extracted using a
method described by Liu R et al. [9] with some modifica-
tions. Serum was separated by centrifugation at 3,000 g
for 10 min, followed by a 15 min high-speed centrifuga-
tion at 12,000 g to completely remove cell debris. The
supernatant serum was recovered and stored at −80°C
until further processing. Total RNA was extracted from
200 μl of serum by acid phenol/chloroform purification
and centrifugation in isopropyl alcohol. Every sample
was all in 20 μl RNA-free ddH2O solution and six
microlitres of total RNA was reverse-transcribed to
cDNA using One Step PrimeScript miRNA cDNA Syn-
thesis Kit (TaKaRa, Dalian, China). Real-time PCR was
performed using a miRcute miRNA qPCR detection kit
(Tiangen, Beijing, China) on the Thermal Cycler Dice
Real Time System (TaKaRa). To calculate the levels of
the miRNAs, synthetic hsa-miR-20a-5p, hsa-let-7a and
hsa-miR-320a at known concentrations (TaKaRa) were
also reverse-transcribed and amplified. The concentra-
tion of each miRNA was then calculated according to
the standard curve. All reactions, including no-template
controls, were run in duplicate.
Serum PG and H. pylori levels
Serum PG concentrations and H.pylori (HP) levels were
determined by enzyme-linked immunosorbent assay
(ELISA) with PGA, PGC and H.pylori ELISA kits (Biohit
Co., Ltd., Helsinki, Finland) [16,26,27]. Samples were
assayed in random order, blind to histology results. Each
batch included commercial controls and blinded plasma
controls to assess laboratory variation. All plasma con-
trols were within the mean ± 2 SDs. Five percent of all
samples were assayed in duplicate.
Statistical analysis
The log10 of the miRNA copy number represented the
levels of the miRNAs, and differences in the levels of
miRNA among the groups as well as in the stratification
analysis were compared by one-way analysis of variance.
Receiver operating characteristic (ROC) curves and the
area under the ROC curve (AUC) were used to evaluate
the diagnostic effects of the miRNAs and to determine
appropriate cut-off points. Medians serum PG concen-
trations were compared among the three groups as well
as in the stratification analysis using Kruskal-Wallis H
tests. Pearson’s correlation coefficient was used to esti-
mate the correlation between miRNAs and PG concen-
trations. The scatter plot was represent the correlation
analysis between the serum miRNA levels and PGA/
PGC ratio, and between PGA and PGC levels. All statis-
tical analyses were performed using SPSS 17.0 software(SPSS Inc. Chicago, USA). A two-sided p value < 0.05
was considered statistically significant.
Results
Demographics of the study subjects
The 291 subjects included 103 controls, 94 patients with
AG and 94 with GC. As shown in Table 1, there were no
significant differences in terms of gender (p = 0.948), age
(p = 0.654) and H.pylori infection status (p = 0.580)
among three groups.
Correlations between expression of serum miRNAs and
gastric diseases
There were no significant differences in the levels of
miR-20a-5p and let-7a among the controls, AG and GC
groups (p = 0.581, 0.445, respectively), but miR-320a
levels decreased gradually among the different groups
(4.99 ± 0.46 vs. 4.94 ± 0.45 vs. 4.90 ± 0.44, p = 0.152,
Table 2).
Stratification by gender and age showed that miR-320a
expression was lower in female GC patients than in con-
trols (p = 0.035), and the difference was especially sig-
nificant in female GC patients older than 60 years,
compared with controls (p = 0.008) (Table 3). The AUC
of miR-320a for detecting female GC patients older than
60 was 0.699. The best cut-off point was 4.76, with a
sensitivity of 65.2% (95%CI = 45.8–84.7%), and a specifi-
city of 68.2% (95%CI = 48.7–87.6%). We also analysis our
data in the H.pylori stratification, but there was no dif-
ference between any of the groups as shown in Table 4.
Correlations between expression of serum miRNAs and
their predicted target PG molecules
For the association analysis, miR-20a-5p expression was
not correlated with PGA levels (r = 0.110, p = 0.269), and
Table 2 Levels of serum miRNAs (mean± SD), PG (median ±
SD) between different gastric disease groups
Variables CON AG GC P-value
miR-20a-5p 3.77 ± 0.74 3.84 ± 0.69 3.83 ± 0.68 0.581
Male 3.80 ± 0.77 3.90 ± 0.73 3.88 ± 0.78 0.59
Female 3.72 ± 0.69 3.73 ± 0.60 3.75 ± 0.47 0.855
let-7a 3.72 ± 0.34 3.77 ± 0.29 3.75 ± 0.28 0.445
Male 3.72 ± 0.31 3.78 ± 0.32 3.77 ± 0.28 0.367
Female 3.71 ± 0.39 3.76 ± 0.24 3.72 ± 0.28 0.93
miR-320a 4.99 ± 0.46 4.94 ± 0.45 4.90 ± 0.44 0.152
Male 5.03 ± 0.49 5.01 ± 0.46 5.00 ± 0.42 0.76
Female 4.93 ± 0.40 4.81 ± 0.39 4.73 ± 0.43 0.035*
PGA 146.3 ± 101.5 111.0 ± 85.4 130.1 ± 107.1 0.044§
PGC 19.2 ± 17.6 14.0 ± 12.2 23.1 ± 23.0 0.003§
PGA/PGC 9.52 ± 4.85 9.52 ± 5.23 7.86 ± 5.46 0.039§
P*:GC vs Control; P§:difference among the three groups. CON: Cases with
minimal superficial gastritis were treated as the controls; AG: atrophic gastritis;
GC: gastric cancer.
Table 4 Expression levels of serum miRNAs (mean ± SD),
PG (median ± SD) between different gastric disease
groups when stratified by H.pylori status
Variables CON AG GC P-value
Hp-
miR-20a-5p 3.83 ± 0.71 3.88 ± 0.59 3.85 ± 0.70 0.926
Male 3.84 ± 0.72 3.90 ± 0.59 3.89 ± 0.34 0.931
Female 3.82 ± 0.71 3.86 ± 0.60 3.75 ± 0.53 0.881
let-7a 3.74 ± 0.31 3.81 ± 0.31 3.76 ± 0.25 0.505
Male 3.73 ± 0.31 3.84 ± 0.34 3.77 ± 0.25 0.36
Female 3.76 ± 0.30 3.76 ± 0.28 3.74 ± 0.27 0.972
miR-320a 5.02 ± 0.48 4.90 ± 0.45 4.91 ± 0.47 0.311
Male 5.03 ± 0.50 4.97 ± 0.48 4.98 ± 0.44 0.813
Female 4.99 ± 0.44 4.81 ± 0.41 4.74 ± 0.50 0.216
PGA 134.99 ± 92.27 96.78 ± 76.05 141.99 ± 125.80 0.056
PGC 15.13 ± 13.67 10.37 ± 9.02 23.15 ± 25.11 0.001
PGA/PGC 10.66 ± 4.81 11.00 ± 6.04 9.17 ± 6.28 0.22
Hp+
miR-20a-5p 3.69 ± 0.78 3.79 ± 0.79 3.81 ± 0.66 0.743
Male 3.75 ± 0.86 3.90 ± 0.31 3.86 ± 0.82 0.785
Female 3.62 ± 0.66 3.53 ± 0.55 3.74 ± 0.43 0.542
let-7a 3.68 ± 0.38 3.74 ± 0.27 3.74 ± 0.31 0.661
Male 3.70 ± 0.31 3.73 ± 0.30 3.77 ± 0.33 0.717
Female 3.66 ± 0.48 3.75 ± 0.18 3.70 ± 0.28 0.795
miR-320a 4.95 ± 0.44 4.98 ± 0.45 4.89 ± 0.40 0.634
Male 5.01 ± 0.49 5.05 ± 4.59 5.05 ± 0.46 0.961
Female 4.87 ± 0.36 4.81 ± 0.38 4.72 ± 0.36 0.471
PGA 162.15 ± 112.44 125.81 ± 92.66 114.74 ± 75.23 0.058
PGC 24.82 ± 20.80 17.86 ± 13.95 23.10 ± 20.16 0.182
PGA/PGC 7.91 ± 4.49 7.97 ± 3.70 6.16 ± 3.57 0.06
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(r = −0.162, -0.102; p = 0.102, 0.306, respectively), but
they were all positively correlated with the PGA/PGC ratio
(r = 0.408, 0.255, 0.324; p= <0.001, 0.009, 0.001, respectively)
(Figure 1). When compared the studied miRNAs and the
predicted target PG molecules with controls, we found
serum PGA levels in GC patients were decreased (130.1 ±
107.1 vs. 146.3 ± 101.5, p= 0.276), and PGC levels in GC pa-
tients were increased (23.1 ± 23.0 vs. 19.2 ± 17.6 p= 0.174),
though the differences were not significant. The PGA/PGC
ratio in the GC group was decreased (7.86 ± 5.46 vs. 9.52 ±
4.85, p= 0.039, Table 2), with a correlation coefficient of
0.727 (Figure 1). Compared with controls, serum miR-320a
levels were decreased (4.90 ± 0.44 vs. 4.99 ± 0.46, p= 0.153)
and serum PGC levels were increased in the GC group
(23.1 ± 23.0 vs. 19.2 ± 17.6 p= 0.174), showing apparently
opposite tendencies, though the differences were not signifi-
cant (Table 2).Discussion
Recent findings have presented serum/plasma miRNAs
as potential biomarkers for several disease conditions,
including human cancers [28-31]. However, studies ofTable 3 Stratification analysis of serum miR-320a level betwe
miRNA CON(n)
miR-320a Male ≥60 5.02 ± 0.44(27)
<60 5.03 ± 0.53(38)
Female ≥60 4.98 ± 0.46(22)
<60 4.88 ± 0.31(16)
P*:GC vs Control. n mean the sample number of each subgroup.serum miRNAs in relation to gastric diseases have been
limited, and no attention has been paid to miRNAs seri-
ally targeting the same gene. Based on a series of
miRNAs predicted by bioinformatic software to target to
PGA and/or PGC, we selected miR-20a-5p, let-7a and
miR-320a for further study. We investigated the poten-
tial of miR-20a-5p, let-7a and miR-320a in the diagnosis
of AG or GC and the correlation of the three miRNAs
with their predicted target molecules PGA, PGC anden different gastric disease groups (mean ± SD)
AG(n) GC(n) P-value
4.96 ± 0.43(28) 4.99 ± 0.46(26) 0.796
5.05 ± 0.49(33) 5.01 ± 0.39(33) 0.859
4.77 ± 0.39(24) 4.63 ± 0.41(23) 0.008*
4.91 ± 0.39(9) 4.92 ± 0.42(12) 0.774
A B
C D
Figure 1 Scatter plot graph. Figure 1-A - C. The scatter plot of serum miRNA levels and their correlations with PGA/PGC ratio from control
group. A. miR-20a-5p; B. let-7a; C. miR-320a. Figure 1-D. The scatter plot of the correlation between serum PGA and PGC levels. All the scatter
plot showed the association analysis of the variants between x and y axis.
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in older female GC patients than in controls, suggesting
that miR-320a may prove a valuable marker for diagnos-
ing older women with GC. miR-20a-5p, let-7a and miR-
320a were positively correlated with the PGA/PGC ratio,
which could indirectly reflect the functional status of the
gastric mucosa.
Several studies have identified tumour-specific miRNAs
alterations in plasma/serum of cancer patients, and have
shown the potential of circulating miRNAs as new non-
invasive biomarkers for cancer screening [12,32]. The
results of our study indicated no differences in serum
miR-20a-5p and let-7a levels among the controls, AG and
GC groups, while miR-320a expression fell throughout the
controls, AG and GC groups. Serum miR-320a levels
were lower in female GC patients than in controls, and
this difference was especially marked in older women,
aged over 60, suggesting that miR-320a may be a new
clinical biomarker for GC diagnosis with population
specificity. Studies of miR-320a to date have been lim-
ited to its roles in regulating the physiological functions
of the blood–brain barrier [33], and in intrahepatic
cholangiocarcinoma [34,35], colon cancer [36] andchildhood leukaemia [37]. To the best of our knowledge,
the current study is the first to report that miR-320a could
act as a serum biomarker of GC, especially in older
women. Although few studies have investigated its mecha-
nisms, some have reported a relationship between its pre-
dicted target PGC and gender, while others reported that
the PGA/PGC ratio was related to age, but only in women
[38,39]. Software has also predicted that miR-320a targets
the estrogen-related receptor gamma (http://www.
targetscan.org/cgi-bin/targetscan/mamm_31/targetscan.
cgi?species=Human&gid=&mir_c=&mir_nc=&mirg=hsa-
miR-320). These lines of evidence all suggest that miR-
320a may play an important role in the development of
GC in women, and could indirectly reflect the func-
tional state of the gastric mucosa. Its use as a biomarker
would be associated with the advantages of non-
invasion, low cost and higher stability. However, further
studies in larger samples are needed to clarify its mech-
anisms and verify its use as a biomarker in older women
with GC. Of course, the changes of miRNAs maybe not
only related with the changes of gastric mucosal func-
tion conditions, but also related with some other fac-
tors, for examples anemia [40], the stimulus of
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proteins involved in miRNAs processing pathway like
Drosha, Dicer and Argonaute [42,43]. The other factors
related should be considered in the further studies in
the future.
Serum PGA and PGC levels seem to be related to gastric
mucosal glandular and cellular quantities, and also indir-
ectly reflect the secretary function of the gastric corpus
and/or gastric antrum. PGA is secreted from the gastric
corpus and gastric angle, while PGC is secreted from all
the stomach, including the corpus, angle and antrum. A
decline in the PGA/PGC ratio reflects the development of
atrophic lesions on the gastric mucosa [16], and a low
PGA/PGC ratio is related to a high risk of GC [38,44,45].
This has therefore been used as an effective parameter for
screening individuals at high risk of GC in the population,
and may be a clinically useful biomarker of GC and pre-
cancerous diseases such as AG [16,38,46,47]. Broutet et al.
reported that although PGC was secreted from different
sites in the stomach, it was related to PGA; while PGA
increased rapidly, PGC varied slightly, and the correl-
ation coefficient reached 0.75 [38]. The current study
also calculated a correlation coefficient between PGA
and PGC of 0.727. This relationship may explain why
the PGA/PGC ratio reflects the functional status of the
gastric mucosa more precisely than either PGA or
PGC alone. Our study found no relationship between
the expression of miR-20a-5p and PGA, let-7a and
PGC, or miR-320a and PGC, but there were positive
correlations between each of the three and the PGA/
PGC ratio which was already known as a useful bio-
marker for disease diagnosis, and the studied miRNAs
were synchronous with the known PGA/PGC ratio
suggesting their potential as useful biomarkers for disease
diagnosis.
Considering H. pylori is an important environmental
factor in the stomach which is also a class Icarcinogen
defined by World Health Organization (WHO), we ana-
lysis the three miRNAs in the HP stratification among
different gastric diseases, but found no difference.
Whether H.pylori and/or other environmental factors
affect this association needs more studies in larger sam-
ples in the future.
There was some limitation in our study. First, the se-
lected miRNAs may functionally target PGA/C and/or at
least was only proof by the bioinformation software, some
evidence for the further functional experiments are
needed. Secondly, correlation of expression in the tissue of
miRNAs and its predicted target protein is needed for fur-
ther investigation. Thirdly, the correlation of miRNAs ex-
pression and clinicopathological characteristics of patients
with gastric cancer, such as Borrmann’s classification,
growth pattern, TNM stage, invasion depth and lymph
node metastasis,et al. were not further analyzed because ofbiopsy-limited information missing. Fourth, the source of
controls was not the normal population but with a min-
imal superficial gastritis according to the pathological
diagnosis, and gastritis was also belongs a cascade of GC
development.
Conclusion
In conclusion, we demonstrated that serum miR-320a
levels were lower in female GC patients aged over 60
than in controls, and may thus represent a valuable
marker for diagnosing GC in this group. And the levels
of miR-20a-5p, let-7a and miR-320a were positively cor-
related with PGA/PGC ratio, which could indirectly re-
flect the functional status of the gastric mucosa.
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